These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 9185705

  • 1. New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145.
    Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Nicholson RI.
    Int J Cancer; 1997 Jun 11; 71(6):1010-8. PubMed ID: 9185705
    [Abstract] [Full Text] [Related]

  • 2. Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways.
    Jones HE, Barrow D, Dutkowski CM, Goddard L, Smith C, Harper ME, Nicholson RI.
    Prostate; 2001 Sep 15; 49(1):38-47. PubMed ID: 11550209
    [Abstract] [Full Text] [Related]

  • 3. Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer.
    Kondapaka BS, Reddy KB.
    Mol Cell Endocrinol; 1996 Mar 01; 117(1):53-8. PubMed ID: 8734473
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868.
    Simpson BJ, Bartlett JM, Macleod KG, Rabiasz G, Miller EP, Rae AL, Gordge P, Leake RE, Miller WR, Smyth J, Langdon SP.
    Br J Cancer; 1999 Mar 01; 79(7-8):1098-103. PubMed ID: 10098742
    [Abstract] [Full Text] [Related]

  • 5. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
    Discafani CM, Carroll ML, Floyd MB, Hollander IJ, Husain Z, Johnson BD, Kitchen D, May MK, Malo MS, Minnick AA, Nilakantan R, Shen R, Wang YF, Wissner A, Greenberger LM.
    Biochem Pharmacol; 1999 Apr 15; 57(8):917-25. PubMed ID: 10086326
    [Abstract] [Full Text] [Related]

  • 6. Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.
    Harper ME, Goddard L, Glynne-Jones E, Assender J, Dutkowski CM, Barrow D, Dewhurst OL, Wakeling AE, Nicholson RI.
    Prostate; 2002 Jun 01; 52(1):59-68. PubMed ID: 11992620
    [Abstract] [Full Text] [Related]

  • 7. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.
    Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA, Woodburn JR.
    Breast Cancer Res Treat; 1996 Jun 01; 38(1):67-73. PubMed ID: 8825124
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.
    Kunkel MW, Hook KE, Howard CT, Przybranowski S, Roberts BJ, Elliott WL, Leopold WR.
    Invest New Drugs; 1996 Jun 01; 13(4):295-302. PubMed ID: 8824347
    [Abstract] [Full Text] [Related]

  • 9. The effect of EGFR-related tyrosine kinase activity inhibition on the growth and invasion mechanisms of prostate carcinoma cell lines.
    Unlü A, Leake RE.
    Int J Biol Markers; 2003 Jun 01; 18(2):139-46. PubMed ID: 12841683
    [Abstract] [Full Text] [Related]

  • 10. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines.
    Guo C, Luttrell LM, Price DT.
    J Urol; 2000 Mar 01; 163(3):1027-32. PubMed ID: 10688043
    [Abstract] [Full Text] [Related]

  • 11. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
    Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M.
    J Cancer Res Clin Oncol; 2003 Mar 01; 129(3):165-74. PubMed ID: 12712332
    [Abstract] [Full Text] [Related]

  • 12. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells.
    Turner T, Chen P, Goodly LJ, Wells A.
    Clin Exp Metastasis; 1996 Sep 01; 14(4):409-18. PubMed ID: 8878415
    [Abstract] [Full Text] [Related]

  • 13. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ.
    J Natl Cancer Inst; 2003 Mar 19; 95(6):458-70. PubMed ID: 12644539
    [Abstract] [Full Text] [Related]

  • 14. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M.
    Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342
    [Abstract] [Full Text] [Related]

  • 15. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
    Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, deKernion JB, Belldegrun AS.
    Cancer; 1996 May 01; 77(9):1862-72. PubMed ID: 8646686
    [Abstract] [Full Text] [Related]

  • 16. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals.
    Xie H, Turner T, Wang MH, Singh RK, Siegal GP, Wells A.
    Clin Exp Metastasis; 1995 Nov 01; 13(6):407-19. PubMed ID: 7586799
    [Abstract] [Full Text] [Related]

  • 17. Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).
    Suarez Pestana E, Greiser U, Sánchez B, Fernández LE, Lage A, Perez R, Böhmer FD.
    Br J Cancer; 1997 Nov 01; 75(2):213-20. PubMed ID: 9010029
    [Abstract] [Full Text] [Related]

  • 18. Interactions between epidermal growth factor-mediated autocrine regulation and linoleic acid-stimulated growth of a human prostate cancer cell line.
    Connolly JM, Rose DP.
    Prostate; 1992 Nov 01; 20(2):151-8. PubMed ID: 1549552
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
    Major TC, Keiser JA.
    J Pharmacol Exp Ther; 1997 Oct 01; 283(1):402-10. PubMed ID: 9336349
    [Abstract] [Full Text] [Related]

  • 20. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
    Modjtahedi H, Affleck K, Stubberfield C, Dean C.
    Int J Oncol; 1998 Aug 01; 13(2):335-42. PubMed ID: 9664130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.